FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220931808> ?p ?o ?g. }

• W4220931808 abstract "In a randomized controlled trial, lenvatinib was non-inferior to sorafenib in overall survival (OS) of patients with unresectable hepatocellular carcinoma (uHCC). This study aimed to compare the effects of sorafenib and lenvatinib as first-line systemic therapy against uHCC with real-world data in chronic hepatitis B patients.This retrospective single-center study involved 132 patients with HBV-related uHCC. Propensity score matching (PSM) was used to balance the baseline characteristics, including age, sex, serum alpha-fetoprotein levels, Child-Pugh class, tumor size, and tumor stage. The primary endpoint was overall survival (OS), and the secondary endpoints included progression-free survival (PFS), time to progression (TTP), and tumor response.After PSM, the final analysis included 44 patients treated with lenvatinib and 88 with sorafenib. The OS (7.0 vs 9.2 months, p = 0.070) and PFS (4.6 vs 2.4 months, p = 0.134) were comparable between the two drugs. Multivariable analysis showed that lenvatinib and sorafenib were not independent prognostic factors of OS (adjusted hazard ratio = 1.41, 95% confidence interval = 0.96-2.08, p = 0.077) after adjustment for baseline alpha-fetoprotein levels, total bilirubin levels, alanine aminotransferase level, performance status, tumor stage, and tumor size. However, the lenvatinib group had a significantly prolonged TTP (5.2 vs 2.5 months, p = 0.018) and a higher objective response rate (18.2% vs 4.5%, p = 0.020) and disease control rate (77.3% vs 47.7%, p = 0.001) than the sorafenib group.Our study demonstrated that lenvatinib had a comparable OS and PFS but longer TTP and better tumor response compared to sorafenib in patients with HBV-related uHCC." @default.
• W4220931808 created "2022-04-03" @default.
• W4220931808 creator A5002354629 @default.
• W4220931808 creator A5018763027 @default.
• W4220931808 creator A5029173537 @default.
• W4220931808 creator A5032849986 @default.
• W4220931808 creator A5042266270 @default.
• W4220931808 creator A5048884497 @default.
• W4220931808 creator A5055208614 @default.
• W4220931808 creator A5057474414 @default.
• W4220931808 creator A5062596225 @default.
• W4220931808 creator A5079442967 @default.
• W4220931808 creator A5088069002 @default.
• W4220931808 creator A5088114646 @default.
• W4220931808 creator A5089681505 @default.
• W4220931808 date "2022-03-25" @default.
• W4220931808 modified "2023-10-09" @default.
• W4220931808 title "Comparison of the outcomes between sorafenib and lenvatinib as the first-line systemic treatment for HBV-associated hepatocellular carcinoma: a propensity score matching analysis" @default.
• W4220931808 cites W1490113896 @default.
• W4220931808 cites W1799522345 @default.
• W4220931808 cites W1971837077 @default.
• W4220931808 cites W1990095055 @default.
• W4220931808 cites W2019294726 @default.
• W4220931808 cites W2036193982 @default.
• W4220931808 cites W2087931424 @default.
• W4220931808 cites W2110643890 @default.
• W4220931808 cites W2140765540 @default.
• W4220931808 cites W2142020092 @default.
• W4220931808 cites W2151600653 @default.
• W4220931808 cites W2159657555 @default.
• W4220931808 cites W2282260497 @default.
• W4220931808 cites W2516849910 @default.
• W4220931808 cites W2626124580 @default.
• W4220931808 cites W2769323635 @default.
• W4220931808 cites W2780491137 @default.
• W4220931808 cites W2787358630 @default.
• W4220931808 cites W2792118167 @default.
• W4220931808 cites W2799933121 @default.
• W4220931808 cites W2898314774 @default.
• W4220931808 cites W2948012654 @default.
• W4220931808 cites W2975593746 @default.
• W4220931808 cites W3028446962 @default.
• W4220931808 cites W3049757680 @default.
• W4220931808 cites W3091975516 @default.
• W4220931808 cites W3102437787 @default.
• W4220931808 cites W3127779614 @default.
• W4220931808 cites W4211061510 @default.
• W4220931808 cites W4230036506 @default.
• W4220931808 cites W4232620598 @default.
• W4220931808 doi "https://doi.org/10.1186/s12876-022-02210-3" @default.
• W4220931808 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35337274" @default.
• W4220931808 hasPublicationYear "2022" @default.
• W4220931808 type Work @default.
• W4220931808 citedByCount "5" @default.
• W4220931808 countsByYear W42209318082022 @default.
• W4220931808 countsByYear W42209318082023 @default.
• W4220931808 crossrefType "journal-article" @default.
• W4220931808 hasAuthorship W4220931808A5002354629 @default.
• W4220931808 hasAuthorship W4220931808A5018763027 @default.
• W4220931808 hasAuthorship W4220931808A5029173537 @default.
• W4220931808 hasAuthorship W4220931808A5032849986 @default.
• W4220931808 hasAuthorship W4220931808A5042266270 @default.
• W4220931808 hasAuthorship W4220931808A5048884497 @default.
• W4220931808 hasAuthorship W4220931808A5055208614 @default.
• W4220931808 hasAuthorship W4220931808A5057474414 @default.
• W4220931808 hasAuthorship W4220931808A5062596225 @default.
• W4220931808 hasAuthorship W4220931808A5079442967 @default.
• W4220931808 hasAuthorship W4220931808A5088069002 @default.
• W4220931808 hasAuthorship W4220931808A5088114646 @default.
• W4220931808 hasAuthorship W4220931808A5089681505 @default.
• W4220931808 hasBestOaLocation W42209318081 @default.
• W4220931808 hasConcept C126322002 @default.
• W4220931808 hasConcept C143998085 @default.
• W4220931808 hasConcept C168563851 @default.
• W4220931808 hasConcept C17923572 @default.
• W4220931808 hasConcept C203092338 @default.
• W4220931808 hasConcept C207103383 @default.
• W4220931808 hasConcept C2776264508 @default.
• W4220931808 hasConcept C2778019345 @default.
• W4220931808 hasConcept C2778695046 @default.
• W4220931808 hasConcept C41260117 @default.
• W4220931808 hasConcept C44249647 @default.
• W4220931808 hasConcept C71924100 @default.
• W4220931808 hasConcept C90924648 @default.
• W4220931808 hasConceptScore W4220931808C126322002 @default.
• W4220931808 hasConceptScore W4220931808C143998085 @default.
• W4220931808 hasConceptScore W4220931808C168563851 @default.
• W4220931808 hasConceptScore W4220931808C17923572 @default.
• W4220931808 hasConceptScore W4220931808C203092338 @default.
• W4220931808 hasConceptScore W4220931808C207103383 @default.
• W4220931808 hasConceptScore W4220931808C2776264508 @default.
• W4220931808 hasConceptScore W4220931808C2778019345 @default.
• W4220931808 hasConceptScore W4220931808C2778695046 @default.
• W4220931808 hasConceptScore W4220931808C41260117 @default.
• W4220931808 hasConceptScore W4220931808C44249647 @default.
• W4220931808 hasConceptScore W4220931808C71924100 @default.
• W4220931808 hasConceptScore W4220931808C90924648 @default.
• W4220931808 hasIssue "1" @default.
• W4220931808 hasLocation W42209318081 @default.
• W4220931808 hasLocation W42209318082 @default.

• next